Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized pick-the-winner design and an option to proceed into a randomized phase 2/3 trial in order to compare the winner with the current SOC (capecitabine).
Epistemonikos ID: 1ddc84c2ecf9f9002e5c60309939377bb732bf8c
First added on: May 10, 2024